|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash, cash equivalents, and restricted cash | ||||||||||||||
| Receivables – net of allowances of $102 and $103 | ||||||||||||||
| Nonrelated party | ||||||||||||||
| Related party | ||||||||||||||
| Total receivables – net of allowances of $102 and $103 | ||||||||||||||
| Inventories | ||||||||||||||
| Contract and other deferred assets | ||||||||||||||
| All other current assets | ||||||||||||||
| Current assets | ||||||||||||||
| Property, plant, and equipment – net | ||||||||||||||
| Goodwill | ||||||||||||||
| Other intangible assets – net | ||||||||||||||
| Deferred income taxes | ||||||||||||||
| All other non-current assets | ||||||||||||||
| Related party | ||||||||||||||
| Total all other non-current assets | ||||||||||||||
| Total assets | ||||||||||||||
| Short-term borrowings | ||||||||||||||
| Accounts payable | ||||||||||||||
| Contract liabilities | ||||||||||||||
| Current compensation and benefits | ||||||||||||||
| All other current liabilities | ||||||||||||||
| Nonrelated party | ||||||||||||||
| Related party | ||||||||||||||
| Total all other current liabilities | ||||||||||||||
| Current liabilities | ||||||||||||||
| Long-term borrowings | ||||||||||||||
| Non-current compensation and benefits | ||||||||||||||
| All other non-current liabilities | ||||||||||||||
| Related party | ||||||||||||||
| Total all other non-current liabilities | ||||||||||||||
| Total liabilities | ||||||||||||||
| Redeemable noncontrolling interests | ||||||||||||||
| Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 459,470,464 shares issued as of June 30, 2026; 458,844,209 shares issued as of December 31, 2025 | ||||||||||||||
| Treasury stock, at cost, 7,785,199 shares as of June 30, 2026 and 3,107,626 shares as of December 31, 2025 | ||||||||||||||
| Additional paid-in capital | ||||||||||||||
| Retained earnings | ||||||||||||||
| Net parent investment | ||||||||||||||
| Accumulated other comprehensive income (loss) – net | ||||||||||||||
| Total equity attributable to GE HealthCare | ||||||||||||||
| Noncontrolling interests | ||||||||||||||
| Total equity | ||||||||||||||
| Total liabilities, redeemable noncontrolling interests, and equity | ||||||||||||||
Loading...
